Morphological features of epithelial-mesenchymal transformation and its effect on tumor progression of breast cancer

Introduction. Breast cancer is in the first place in the structure of morbidity among all malignant neoplasms in women. The prognosis of the disease depends on the tumor degree, including the presence of epithelial-mesenchymal transformation (EMT), the degree of invasion, the proliferative index, the preservation or absence of estrogen, progesterone, and epidermal growth factor receptors.

Aim: To study the immunohistochemical and morphological characteristics of the epithelial-mesenchymal transformation of breast cancer.

Material and Methods. Immunohistochemical study with antibodies to AE1/AE3, HMW, CK18, Snail, HER2/neu, E-cadherin, Vimentin, α-SMA, CD34, Ki-67 and p63 was performed in 60 patients of different age with breast cancer. Native preparations were stained with picrofuchsin according to van Gieson Alcian blue. Inflammatory infiltrate cells were examined for antibodies CD45, CD3, CD4, CD8, CD20, CD68.

Results. In ductal carcinoma, positive expression for estrogen and progesterone was found in 82.7% and 86.3%, respectively, the proliferation index ranged before 66,6%, and p-53 was positive in 97%. In lobular cancer, positive expression to estrogen and progesterone was observed in 83.4% and 66.6%, respectively, the index of proliferative activity at the level of 50%, and p-53 was positive in 66.6%. Positive moderate expression of HER-2/neu was determined in 47% of ductal and 50% of lobular cancers. Estrogen plays an important role in the development of invasive breast cancer, leads to tumor progression and contributes to EMT. EMT, in turn, leads to the expression of E-cadherin associated with a worse survival prognosis. EMT indirectly leads to the intensification of angiogenesis, and the presence of a large number of newly formed vessels increases the risk of metastasis. Histochemical methods were used to determine the growth of fibrous tissue around invasively growing cancer complexes. Cells located perifocally looked like fibrobla ts, immunohistochemically moderately expressed Vimentin and weakly expressed pancytokeratin, which proved the tumor nature of the cells and the acquisition of mesenchymal features by them. The inflammatory infiltrate along the periphery of the tumor growth consisted mainly of T- and B-lymphocytes, and around the cancer complexes - of B-lymphocytes and macrophages.

Conclusion.  The  study  of  the  immunohistochemical  tumor  phenotype  will  make  it  possible  to  prescribe  adequate polychemotherapy and determine the prognosis of the course of the disease.

1. Thiery J.P., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. DOI: 10.1016/j.cell.2009.11.007.

2. Kokorev A.V., Moguileva A.S., Puirveev S.S., Lebedenko E.A., Nekrasov M.S. Epithelial-mesenchymal transition and its role in metastasis processes. Forcipe. 2020;3(1):173–174. (In Russ.).

3. Cumin C., Huang Y.L., Everest-Dass A., Jacob F. Deciphering the importance of glycosphingolipids on cellular and molecular mechanisms associated with epithelial-to-mesenchymal transition in cancer. Biomolecules. 2021;11(1):62. DOI: 10.3390/biom11010062.

4. Nieto M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 2011;27:347–376. DOI: 10.1146/annurev-cellbio-092910-154036.

5. Gaponova A.V., Rodin S., Mazina A.A., Volchkov P.V. Epithelial-mesenchymal transition: Role in cancer progression and the perspectives of antitumor treatment. Acta Naturae. 2020;12;3:4–23. (In Russ.). DOI: 10.32607/actanaturae.11010.

6. Abaurrea A., Araujo A.M., Caffarel M.M. The role of the IL-6 сytokine family in еpithelial-mesenchymal plasticity in сancer progression. Int. J. Mol. Sci. 2021;22(15):8334. DOI: 10.3390/ijms22158334.

7. Chou M.Y., Yang M.H. Interplay of immunometabolism and epithelial-mesenchymal transition in the tumor microenvironment. Int. J. Mol. Sci. 2021;13;22(18):9878. DOI: 10.3390/ijms22189878.

8. Saitoh M. Involvement of partial EMT in cancer progression. J. Biochem. 2018;164(4):257–264. DOI: 10.1093/jb/mvy047.

9. Zasadkevich Yu.M., Brilliant A.A., Sazonov S.V. Expression of epithelial-mesenchymal transition markers E-cadherin and vimentin in different immunohistochemical variants of breast carcinoma. Ural Medical Journal. 2014;116(2):29–32. (In Russ.).

10. Radisky D.C. Epithelial-mesenchymal transition. J. Cell Sci. 2005;118(19):4325–4326. DOI: 10.1242/jcs.02552.

11. Kondratyk R.B., Grekov I.S., Yarkov A.M., Rusina A.A., Shvorob D.S. The role of epithelial-mesenchymal transition in carcinomas by different localizations (Part 1). Neoplasm. 2021;13(2):91–95. (In Russ.).

12. Ramesh V., Brabletz T., Ceppi P. Targeting EMT in сancer with repurposed metabolic inhibitors. Trends Cancer. 2020;6(11):942–950. DOI: 10.1016/j.trecan.2020.06.005.